Experienced Life Science entrepreneur, executive & Board member. Recently exited medical device company "Phagenesis Ltd" to Nestle Health Sciences (strong returns to all shareholders), where he was a key member of the management team and Board. Fred is also a founder and Exec Director of Solus Scientific, which he has built to profitability and strong growth.

Director of Anglo Scientific; MBA London Business School; Harvard undergraduate

A Director of Anglo Scientific, Will has founded and led the growth of numerous early stage technology businesses where he has had operational and Board roles (including in vitro diagnostics). He is also an adviser to the Singapore government for new medical technologies.

Prior to becoming an entrepreneur, Will worked in M&A at Lehman Brothers, Barclays Capital and JP Morgan

Alex joined Apta from Maccine, a Contract Research Organisation for large pharma, where he spent 7 years, most recently as CEO (formerly COO and CSO). Prior to Maccine, he was with GlaxoSmithKline (UK & Singapore) for 9 years as a principal scientist & investigator.

Previously co-founder, CEO & President of AtheroGenics (IPO on NASDAQ); Founding Director, Inhibitex, (IPO on NASDAQ and subsequently sold to Bristol Myers for $2.5bn); Boards of numerous other biotech companies inlcuding Transcardiac Therapeutics, Somatocor, EmTech Bio; past Chairman Georgia Bio & Board of US Biotech Industry Association

Prof. Hematology & Oncology at Emory University; Ex President of the Federation of American Societies for Experimental Biology and Deputy National Vice President for Research of the American Cancer Society.

Neurosurgeon and Prof. at Harvard Medical and Queens University Belfast. $10bn of value realization from commercializing early stage biotechnology and medical devices as a venture capitalist. Ex Chair of Scientific Advisory Boards for Lundbeck, Dupont & RBC. Advisor to the US FDA.

Former President & CEO of Chimerix (NASDAQ:CMRX), BioMedical Enterprises, Alteon and Biocyte Corp; Co-founder & VP at The Liposome Company; 10+ years on the Board of BIO & Secretary of BIO’s Emerging Companies Section